Hepatitis B virus vaccine: A randomized trial of a reduced dose regimen in hemodialysis patients

G. R. Aronoff, D. R. Maxwell, Byron Batteiger, N. S. Fineberg

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To test the hypothesis that increasing the dose enhances response to hepatitis B virus vaccine in hemodialysis patients, we performed a randomized, double blind, controlled clinical trial. Twenty-four hemodialysis patients were randomly assigned to receive either three 20 mcg or the recommended three 40 mcg intramuscular injections over 6 months. In addition, 19 normal volunteers also received three 20 mcg doses of the vaccine. The presence of Anti-HBs was determined qualitatively and quantitatively. Non-uremic subjects seroconverted more frequently than did either of the dialysis patient groups. Doubling the individual doses of vaccine did not improve the response of the dialysis patients. We conclude that the response to the vaccine is not diminished when dialysis patients are given half the recommended dose of the vaccine and that the cost of vaccinating this high-risk population could be substantially reduced.

Original languageEnglish
Pages (from-to)170-172
Number of pages3
JournalAmerican Journal of Kidney Diseases
Volume6
Issue number3
StatePublished - 1985

Fingerprint

Hepatitis B Vaccines
Hepatitis B virus
Renal Dialysis
Vaccines
Dialysis
Intramuscular Injections
Controlled Clinical Trials
Healthy Volunteers
Costs and Cost Analysis
Population

ASJC Scopus subject areas

  • Nephrology

Cite this

Hepatitis B virus vaccine : A randomized trial of a reduced dose regimen in hemodialysis patients. / Aronoff, G. R.; Maxwell, D. R.; Batteiger, Byron; Fineberg, N. S.

In: American Journal of Kidney Diseases, Vol. 6, No. 3, 1985, p. 170-172.

Research output: Contribution to journalArticle

@article{dc916e2f601649f4bc054487d09971ba,
title = "Hepatitis B virus vaccine: A randomized trial of a reduced dose regimen in hemodialysis patients",
abstract = "To test the hypothesis that increasing the dose enhances response to hepatitis B virus vaccine in hemodialysis patients, we performed a randomized, double blind, controlled clinical trial. Twenty-four hemodialysis patients were randomly assigned to receive either three 20 mcg or the recommended three 40 mcg intramuscular injections over 6 months. In addition, 19 normal volunteers also received three 20 mcg doses of the vaccine. The presence of Anti-HBs was determined qualitatively and quantitatively. Non-uremic subjects seroconverted more frequently than did either of the dialysis patient groups. Doubling the individual doses of vaccine did not improve the response of the dialysis patients. We conclude that the response to the vaccine is not diminished when dialysis patients are given half the recommended dose of the vaccine and that the cost of vaccinating this high-risk population could be substantially reduced.",
author = "Aronoff, {G. R.} and Maxwell, {D. R.} and Byron Batteiger and Fineberg, {N. S.}",
year = "1985",
language = "English",
volume = "6",
pages = "170--172",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Hepatitis B virus vaccine

T2 - A randomized trial of a reduced dose regimen in hemodialysis patients

AU - Aronoff, G. R.

AU - Maxwell, D. R.

AU - Batteiger, Byron

AU - Fineberg, N. S.

PY - 1985

Y1 - 1985

N2 - To test the hypothesis that increasing the dose enhances response to hepatitis B virus vaccine in hemodialysis patients, we performed a randomized, double blind, controlled clinical trial. Twenty-four hemodialysis patients were randomly assigned to receive either three 20 mcg or the recommended three 40 mcg intramuscular injections over 6 months. In addition, 19 normal volunteers also received three 20 mcg doses of the vaccine. The presence of Anti-HBs was determined qualitatively and quantitatively. Non-uremic subjects seroconverted more frequently than did either of the dialysis patient groups. Doubling the individual doses of vaccine did not improve the response of the dialysis patients. We conclude that the response to the vaccine is not diminished when dialysis patients are given half the recommended dose of the vaccine and that the cost of vaccinating this high-risk population could be substantially reduced.

AB - To test the hypothesis that increasing the dose enhances response to hepatitis B virus vaccine in hemodialysis patients, we performed a randomized, double blind, controlled clinical trial. Twenty-four hemodialysis patients were randomly assigned to receive either three 20 mcg or the recommended three 40 mcg intramuscular injections over 6 months. In addition, 19 normal volunteers also received three 20 mcg doses of the vaccine. The presence of Anti-HBs was determined qualitatively and quantitatively. Non-uremic subjects seroconverted more frequently than did either of the dialysis patient groups. Doubling the individual doses of vaccine did not improve the response of the dialysis patients. We conclude that the response to the vaccine is not diminished when dialysis patients are given half the recommended dose of the vaccine and that the cost of vaccinating this high-risk population could be substantially reduced.

UR - http://www.scopus.com/inward/record.url?scp=0022391248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022391248&partnerID=8YFLogxK

M3 - Article

C2 - 3898825

AN - SCOPUS:0022391248

VL - 6

SP - 170

EP - 172

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 3

ER -